Unbelievable Nonprofit Bet on Biomarker Pays off for Parkinson’s 💰🎯🧠 (news)
Using the Whole Whale - A Nonprofit Podcast
Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In 2010, the Michael J. Fox Foundation made a BIG bet on investing in researching a biomarker for Parkinson’s Disease (PPMI project). On April 12th it was announced that the bet paid off.
Researchers announced that with the α-synuclein seeding amplification assay (αSyn-SAA), they now have a tool capable of detecting abnormal alpha-synuclein, a key pathology in Parkinson's disease (PD). The breakthrough marks a significant shift in understanding, diagnosing, and treating PD. The assay was validated with 93% accuracy and promises to enable earlier diagnoses, targeted treatments, and more efficient drug development. Efforts are underway to develop αSyn-SAA for the widespread use and optimize it to measure the amount of alpha-synuclein present, potentially through blood draws or nasal swabs. This development holds tremendous potential for transforming research and care for those living with Parkinson's disease.
Summary
- Nonprofit praises automatic expungement program that aims to help millions | FOX 17
- Donations Decline for the First Time Since 2012, Fundraising Effectiveness Project Data Shows | NonProfit PRO
- These startups and nonprofits are keeping the abortion pill accessible | Fast Company
Sponsored: Looking for trusted nonprofit consultants in New York - or California? Nonprofit.ist has you covered.